Akumin (AKUMQ) 10-Q 9 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	333-261815
Entity Registrant Name	AKUMIN INC.
Entity Incorporation, State or Country Code	A6
Entity Address, Address Line One	8300 W. Sunrise Boulevard
Entity Address, City or Town	Plantation
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33322
City Area Code	844
Local Phone Number	730-0050
Title of 12(b) Security	Common Shares
Trading Symbol	AKU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Common Stock, Shares Outstanding		89,516,513
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001776197
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 38,447	$ 48,419
Accounts receivable	126,145	121,525
Prepaid expenses	9,385	8,196
Other current assets	6,826	7,025
Total current assets	180,803	185,165
Property and equipment, net	231,297	259,122
Operating lease right-of-use assets	179,954	194,565
Goodwill	840,788	840,353
Other intangible assets, net	403,980	414,146
Other assets	24,671	25,475
Total assets	1,861,493	1,918,826
Current liabilities:
Accounts payable	33,787	34,326
Current portion of long-term debt	16,299	14,789
Current portion of obligations under finance leases	5,972	6,460
Current portion of obligations under operating leases	20,122	20,794
Accrued liabilities	90,916	87,813
Total current liabilities	167,096	164,182
Long-term debt, net of current portion	1,220,823	1,197,596
Obligations under finance leases, net of current portion	13,872	15,951
Obligations under operating leases, net of current portion	171,044	184,375
Other liabilities	32,124	35,574
Total liabilities	1,604,959	1,597,678
Redeemable noncontrolling interests	36,042	37,469
Shareholders’ equity:
Common stock, no par value; unlimited number of shares authorized; 89,516,513 and 89,026,997 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	230,414	228,595
Accumulated other comprehensive income	80	18
Accumulated deficit	(184,704)	(123,424)
Total shareholders’ equity	45,790	105,189
Noncontrolling interests	174,702	178,490
Total equity	220,492	283,679
Total liabilities, redeemable noncontrolling interests and equity	$ 1,861,493	$ 1,918,826

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock issued (in shares)	89,516,513	89,026,997
Common stock outstanding (in shares)	89,516,513	89,026,997

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 192,128	$ 69,496	$ 378,391	$ 133,459
Operating expenses:
Cost of operations, excluding depreciation and amortization	154,574	57,768	309,735	112,910
Depreciation and amortization	25,200	4,584	49,931	9,073
Restructuring charges	7,244	0	7,324	0
Severance and related costs	5,559	0	7,797	0
Settlements, recoveries and related costs	814	(318)	677	(341)
Stock-based compensation	758	785	1,819	1,212
Other operating expense, net	586	255	579	346
Total operating expenses	194,735	63,074	377,862	123,200
Income (loss) from operations	(2,607)	6,422	529	10,259
Other expense (income):
Interest expense	29,290	8,920	57,971	17,288
Acquisition-related costs	86	4,350	468	5,628
Other non-operating income, net	(2,421)	0	(2,479)	(3,366)
Total other expense, net	26,955	13,270	55,960	19,550
Loss before income taxes	(29,562)	(6,848)	(55,431)	(9,291)
Income tax expense (benefit)	(3,483)	6	(2,920)	71
Net loss	(26,079)	(6,854)	(52,511)	(9,362)
Less: Net income attributable to noncontrolling interests	4,390	502	8,769	871
Net loss attributable to common shareholders	(30,469)	(7,356)	(61,280)	(10,233)
Comprehensive loss, net of taxes:
Net loss	(26,079)	(6,854)	(52,511)	(9,362)
Other comprehensive income:
Unrealized gain on hedging transactions, net of taxes	7	0	36	0
Reclassification adjustment for losses included in net loss, net of taxes	9	0	26	0
Other comprehensive income	16	0	62	0
Comprehensive loss, net of taxes	(26,063)	(6,854)	(52,449)	(9,362)
Less: Comprehensive income attributable to noncontrolling interests	4,390	502	8,769	871
Comprehensive loss attributable to common shareholders	$ (30,453)	$ (7,356)	$ (61,218)	$ (10,233)
Net loss per share attributable to common shareholders:
Basic (in dollars per share)	$ (0.34)	$ (0.10)	$ (0.69)	$ (0.15)
Diluted (in dollars per share)	$ (0.34)	$ (0.10)	$ (0.69)	$ (0.15)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Shareholders’ Equity	Common Stock	Accumulated Other Comprehensive Income	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020			70,178,428
Beginning balance at Dec. 31, 2020	$ 85,170	$ 80,832	$ 160,965	$ 0	$ (80,133)	$ 4,338
Net loss	(9,362)	(10,233)			(10,233)	871
Issuance of common stock for acquisition consideration (in shares)			974,999
Issuance of common stock for acquisition consideration	3,012	3,012	$ 3,012
Stock options exercised (in shares)			150,000
Stock options exercised	75	75	$ 75
Stock-based compensation	1,212	1,212	$ 1,212
Other comprehensive income	0
Distributions paid to noncontrolling interests	(1,006)					(1,006)
Ending balance (in shares) at Jun. 30, 2021			71,303,427
Ending Balance at Jun. 30, 2021	79,101	74,898	$ 165,264	0	(90,366)	4,203
Beginning balance (in shares) at Mar. 31, 2021			70,178,428
Beginning balance at Mar. 31, 2021	82,640	78,382	$ 161,392	0	(83,010)	4,258
Net loss	(6,854)	(7,356)			(7,356)	502
Issuance of common stock for acquisition consideration (in shares)			974,999
Issuance of common stock for acquisition consideration	3,012	3,012	$ 3,012
Stock options exercised (in shares)			150,000
Stock options exercised	75	75	$ 75
Stock-based compensation	785	785	$ 785
Other comprehensive income	0
Distributions paid to noncontrolling interests	(557)					(557)
Ending balance (in shares) at Jun. 30, 2021			71,303,427
Ending Balance at Jun. 30, 2021	79,101	74,898	$ 165,264	0	(90,366)	4,203
Beginning balance (in shares) at Dec. 31, 2021			89,026,997
Beginning balance at Dec. 31, 2021	283,679	105,189	$ 228,595	18	(123,424)	178,490
Net income (loss), net of the net income attributable to redeemable noncontrolling interests	(53,625)	(61,280)			(61,280)	7,655
Net loss	(52,511)
Issuance of common stock under stock-based awards (in shares)			489,516
Stock-based compensation	1,819	1,819	$ 1,819
Other comprehensive income	62	62		62
Distributions paid to noncontrolling interests	(11,604)					(11,604)
Other equity transactions	161					161
Ending balance (in shares) at Jun. 30, 2022			89,516,513
Ending Balance at Jun. 30, 2022	220,492	45,790	$ 230,414	80	(184,704)	174,702
Beginning balance (in shares) at Mar. 31, 2022			89,516,513
Beginning balance at Mar. 31, 2022	252,209	75,485	$ 229,656	64	(154,235)	176,724
Net income (loss), net of the net income attributable to redeemable noncontrolling interests	(26,613)	(30,469)			(30,469)	3,856
Net loss	(26,079)
Stock-based compensation	758	758	$ 758
Other comprehensive income	16	16		16
Distributions paid to noncontrolling interests	(5,878)					(5,878)
Ending balance (in shares) at Jun. 30, 2022			89,516,513
Ending Balance at Jun. 30, 2022	$ 220,492	$ 45,790	$ 230,414	$ 80	$ (184,704)	$ 174,702

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities:
Net loss	$ (52,511)	$ (9,362)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	49,931	9,073
Stock-based compensation	1,819	1,212
Non-cash interest expense	24,604	0
Amortization of deferred financing costs and accretion of discount/premium on long-term debt	54	923
Deferred income taxes	(3,368)	0
Distributions from unconsolidated investees	915	0
Earnings from unconsolidated investees	(488)	0
Other non-cash items, net	(498)	(3,020)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(4,547)	(1,688)
Prepaid expenses and other assets	(1,919)	824
Accounts payable and other liabilities	6,502	3,895
Operating lease liabilities and right-of-use assets	585	904
Net cash provided by operating activities	21,079	2,761
Investing activities:
Purchases of property and equipment	(15,466)	(2,584)
Business acquisitions, net of cash acquired	0	(35,749)
Other investing activities	963	(4,588)
Net cash used in investing activities	(14,503)	(42,921)
Financing activities:
Proceeds from revolving loan	20,000	0
Principal payments on revolving loan	(20,000)	0
Proceeds from long-term debt	10,292	78,750
Principal payments on long-term debt	(8,734)	(200)
Principal payments on finance leases	(3,961)	(1,615)
Payment of debt issuance costs	0	(1,162)
Payment of earn-out liability	0	(4,689)
Proceeds from issuance of common stock	0	75
Distributions paid to noncontrolling interests	(14,145)	(1,006)
Net cash provided by (used in) financing activities	(16,548)	70,153
Net increase (decrease) in cash and cash equivalents	(9,972)	29,993
Cash and cash equivalents, beginning of period	48,419	44,396
Cash and cash equivalents, end of period	38,447	74,389
Supplemental disclosure of cash flow information:
Interest paid	32,439	16,915
Income taxes paid, net	502	241
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases in accounts payable and other accrued liabilities	4,852	323
Derecognition of operating lease right-of-use assets and lease liabilities associated with lease terminations	3,635	929
Equipment acquired in exchange for finance lease obligations	1,433	686
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$ 668	$ 1,649

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by Akumin Inc. (the “Company” or “Akumin”) and do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. (“GAAP”). In the opinion of management, all normal recurring accruals and adjustments considered necessary for a fair presentation have been included. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements for the year ended December 31, 2021. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

New Accounting Standards

New Accounting Standards	6 Months Ended
	Jun. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) In April 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This guidance clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. This ASU is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this standard as of January 1, 2022 and it did not have a material impact on the Company’s condensed consolidated financial statements. ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance , which aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. ASU 2021-10 also adds a new Topic—ASC 832, Government Assistance —to the FASB’s Codification. The disclosure requirements only apply to transactions with a government that are accounted for by analogizing to either a grant model or a contribution model. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this standard as of January 1, 2022 and it did not have a material impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Standards Not Yet Effective ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , and related clarifying standards, which replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. For all other entities, this ASU is effective for fiscal years beginning after December 15, 2022. The Company is considered an Emerging Growth Company as classified by the Securities and Exchange Commission (“SEC”), which gives the Company relief in the timing of implementation of this standard by allowing the private company timing for adoption. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued. For all entities, the guidance is effective upon issuance and generally can be applied through December 31, 2022. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2021-01, Reference Rate Reform (Topic 848): Scope In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope . This ASU clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain option expedients and exceptions in Topic 848. The guidance is effective upon issuance and generally can be applied through December 31, 2022. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805) In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , creating an exception to the recognition and measurement principles in ASC 805, Business Combinations . The amendments require an acquirer to use the guidance in ASC 606, Revenue from Contracts with Customers , rather than using fair value, when recognizing and measuring contract assets and contract liabilities related to customer contracts assumed in a business combination. In addition, the amendments clarify that all contracts requiring the recognition of assets and liabilities in accordance with the guidance in ASC 606, such as contract liabilities derived from the sale of nonfinancial assets within the scope of ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets

Alliance Acquisition

Alliance Acquisition	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Alliance Acquisition	Alliance AcquisitionOn September 1, 2021, the Company acquired all of the issued and outstanding common stock of Thaihot Investment Company US Limited, which owns 100% of the common stock of Alliance, from Thaihot Investment Co., Ltd. for a total purchase price of $785.6 million (the “Alliance Acquisition”). The acquisition included Alliance’s ownership interests in its joint ventures, which had a preliminary fair value of $212.0 million on the acquisition date. As of the acquisition date, the Company had preliminarily estimated the fair value of the assets acquired and liabilities assumed and allocated a portion of the total purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the date of the acquisition. Noncontrolling interests have also been recorded at fair value as of the acquisition date. The fair value of the total enterprise applicable to joint ventures has been allocated to the individual joint ventures. During the six months ended June 30, 2022, the Company updated the preliminary assessment of the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in certain changes to the preliminary amounts previously recorded. These changes were composed primarily of (i) a decrease in property and equipment acquired of $0.5 million due to a refinement in the valuation analysis, (ii) a decrease in other liabilities of $0.1 million due to adjustments in estimated accrued liabilities, (iii) a decrease in equipment debt of $0.1 million due to an adjustment in the carrying value of the liability, and (iv) an increase in noncontrolling interest of $0.2 million due to a refinement in the valuation analysis. The net effect of the changes to the preliminary fair value of the assets acquired and liabilities assumed resulted in an increase in goodwill of $0.4 million. The final determination of the fair value of certain assets acquired and liabilities assumed, including deferred tax liabilities and the assignment of goodwill to reporting units, was not complete as of June 30, 2022 but will be finalized within the allowable one-year measurement period. The following table summarizes the revised preliminary assessment of fair value of the assets acquired and liabilities assumed as of the date of the acquisition: (in thousands) Assets acquired: Cash and cash equivalents $ 26,125 Net working capital 14,221 Property and equipment 205,940 Operating lease right-of-use assets 69,919 Goodwill 456,195 Intangibles – Customer contracts 266,224 Intangibles – Trade names 69,108 Intangibles – Third party management agreements 10,200 Intangibles – Certificates of need 69,558 Other assets 8,170 1,195,660 Liabilities assumed: Equipment debt 54,539 Obligations under finance leases 9,041 Obligations under operating leases 74,290 Deferred tax liabilities 52,760 Other liabilities 7,234 197,864 Net assets acquired 997,796 Less redeemable noncontrolling interests 37,040 Less noncontrolling interests 175,140 Purchase price $ 785,616

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities In accordance with consolidation guidance, a reporting entity with a variable interest in another entity is required to include the assets and liabilities and revenues and expenses of that separate entity (i.e., consolidate with the financial statements of the reporting entity) when the variable interest is determined to be a controlling financial interest. A reporting entity is considered to have a controlling financial interest in a variable interest entity (“VIE”) if (i) the reporting entity has the power to direct the activities of the VIE that most significantly impacts its economic performance and (ii) the reporting entity has the obligation to absorb losses of the VIE that could be potentially significant to the VIE. As a result of the financial relationship established between the Company and certain entities (the “Revenue Practices”) through respective management service agreements, the Revenue Practices individually qualify as VIEs as the Company, which provides them non-medical, technical and administrative services, has the power to direct their respective activities and the obligation to absorb their gains and losses. As a result, the Company is considered the primary beneficiary of the Revenue Practices, and accordingly, the assets and liabilities and revenues and expenses of the Revenue Practices are included in the condensed consolidated financial statements. The following information excludes any intercompany transactions and costs allocated by the Company to the Revenue Practices. As of June 30, 2022 and December 31, 2021, the Revenue Practices’ assets included in the Company’s condensed consolidated balance sheets were $23.4 million and $20.4 million, respectively, and liabilities included in the Company’s condensed consolidated balance sheets were $0 and $0.6 million, respectively. The assets of the Revenue Practices can only be used to settle their obligations. During the six months ended June 30, 2022 and 2021, the Revenue Practices’ revenues were $92.8 million and $83.3 million, respectively, and the net cash provided by operating activities was $93.2 million and $90.2 million, respectively.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: (in thousands) June 30, December 31, Medical equipment $ 236,007 $ 227,796 Leasehold improvements 41,274 39,763 Equipment under finance leases 35,574 34,597 Office and computer equipment 19,246 16,701 Transportation and service equipment 11,672 8,996 Furniture and fixtures 3,399 3,130 Construction in progress 1,186 6,423 348,358 337,406 Less accumulated depreciation 117,061 78,284 $ 231,297 $ 259,122 Depreciation expense was $20.2 million and $3.9 million for the three months ended June 30, 2022 and 2021, respectively, and $39.9 million and $7.7 million for the six months ended June 30, 2022 and 2021, respectively.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Changes in the carrying amount of goodwill are as follows: (in thousands) Radiology Oncology Total Balance, December 31, 2021 $ 681,993 $ 158,360 $ 840,353 Adjustments 360 75 435 Balance, June 30, 2022 $ 682,353 $ 158,435 $ 840,788 The Company tests its goodwill and indefinite-lived intangible assets annually or more frequently depending on certain impairment indicators. Such indicators include a significant decline in expected future cash flows due to changes in company-specific factors or the broader business climate. As of June 30, 2022, there were no indications of impairment of the Company’s goodwill balances.

Other Intangible Assets

Other Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	Other Intangible Assets Other intangible assets consist of the following: (dollars in thousands) Weighted June 30, 2022 December 31, 2021 Gross Accumulated Other Gross Accumulated Other Finite-lived intangible assets: Customer contracts 20 $ 266,059 $ (11,116) $ 254,943 $ 266,224 $ (4,437) $ 261,787 Trade names 18 77,466 (8,618) 68,848 77,466 (6,054) 71,412 Management agreements 17 10,200 (500) 9,700 10,200 (200) 10,000 Other 4 4,814 (3,883) 931 4,814 (3,425) 1,389 Total $ 358,539 $ (24,117) 334,422 $ 358,704 $ (14,116) 344,588 Certificates of Need 69,558 69,558 Total other intangible assets $ 403,980 $ 414,146 The Company performs an impairment test when indicators of impairment are present. As of June 30, 2022, there were no indications of impairment of the Company’s other intangible assets balances.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Long-term debt consists of the following: (in thousands) June 30, December 31, 2028 Senior Notes $ 375,000 $ 375,000 2025 Senior Notes 475,000 475,000 Subordinated Notes 397,074 372,470 Equipment Debt 60,212 58,827 1,307,286 1,281,297 Debt discount and deferred issuance costs (70,164) (68,912) 1,237,122 1,212,385 Less current portion 16,299 14,789 Long-term debt, net of current portion $ 1,220,823 $ 1,197,596 During the six months ended June 30, 2022, the Company elected to pay interest in-kind on the Subordinated Notes pursuant to the original agreement and, accordingly, $24.6 million of accrued interest was added to the principal balance of the Subordinated Notes. Certain of the debt obligations are subject to covenants with which the Company must comply on a quarterly or annual basis. The Company was in compliance with all such covenants as of June 30, 2022.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following: (in thousands) June 30, December 31, Accrued compensation and related expenses $ 35,525 $ 26,486 Accrued interest expense 17,823 16,840 Other 37,568 44,487 $ 90,916 $ 87,813

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests The Company has noncontrolling interests with redemption features. These redemption features could require the Company to make an offer to purchase the noncontrolling interests in the case of certain events, including (i) the expiration or termination of certain operating agreements of the joint venture, or (ii) the noncontrolling interests’ tax-exempt status is jeopardized by the joint venture. As of June 30, 2022, the Company holds redeemable noncontrolling interests of $36.0 million, which are not currently redeemable or probable of becoming redeemable. The redemption of these noncontrolling interests is not solely within the Company’s control, therefore, they are presented in the temporary equity section of the Company’s condensed consolidated balance sheets. The Company does not believe it is probable the redemption features related to these noncontrolling interest securities will be triggered as the triggering events are generally not probable until they occur. As such, these noncontrolling interests have not been remeasured to redemption value. The following is a rollforward of the activity in the redeemable noncontrolling interests for the six months ended June 30, 2022: (in thousands) Balance, December 31, 2021 $ 37,469 Net income attributable to redeemable noncontrolling interests 1,114 Distributions paid to redeemable noncontrolling interests (2,541) Balance, June 30, 2022 $ 36,042

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2022
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments Assets and Liabilities that are Measured at Fair Value on a Recurring Basis The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis: Fair Value as of June 30, 2022 Fair Value as of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Current and long-term assets: Interest rate contracts $ — $ 39 $ — $ 39 $ — $ 3 $ — $ 3 Current and long-term liabilities: Derivative in subordinated notes $ — $ — $ 6,683 $ 6,683 $ — $ — $ 7,522 $ 7,522 Interest rate contracts $ — $ — $ — $ — $ — $ 53 $ — $ 53 The derivative in subordinated notes relates to the Change of Control Redemption Election included in the Subordinated Notes (see Note 8). The fair value of the Change of Control Redemption Election liability was determined using a probability weighted scenario analysis regarding a potential change of control during the term. The estimated fair values of the Change of Control Redemption Election as of June 30, 2022 and December 31, 2021 use unobservable inputs for probability weighted time until an exit event of 3.9 years and 4.2 years, respectively, and an exit event probability weighting of 24.0% and 24.5%, respectively. The following is a reconciliation of the opening and closing balances for the liability related to the embedded derivative included in the Subordinated Notes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2022: (in thousands) Balance, December 31, 2021 $ 7,522 Change in fair value (839) Balance, June 30, 2022 $ 6,683 The $0.8 million change in the fair value of the derivative in subordinated notes was recorded as a gain and included in other non-operating income, net in the Company's condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2022. The Company’s interest rate contracts are primarily pay-fixed, receive-variable interest rate swaps related to certain of the Company’s equipment debt. The amount that the Company expects to reclassify from accumulated other comprehensive income to interest expense over the next twelve months is immaterial. Assets and Liabilities for which Fair Value is only Disclosed The estimated fair values of other current and non-current liabilities are as follows: (in thousands) June 30, December 31, 2028 Senior Notes $ 264,375 $ 345,938 2025 Senior Notes 365,750 446,500 Subordinated Notes 249,197 323,620 Equipment Debt 51,862 56,879 $ 931,184 $ 1,172,937 As of June 30, 2022 and December 31, 2021, the estimated fair values of the 2028 Senior Notes and 2025 Senior Notes were determined using Level 2 inputs and the estimated fair values of the Subordinated Notes and Equipment Debt were determined using Level 3 inputs. The carrying value of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and the current portion of lease liabilities approximates their fair value given their short-term nature. The carrying value of the non-current portion of lease liabilities approximates their fair value given the difference between the discount rates used to recognize the liabilities in the condensed consolidated balance sheets and the normalized expected market rates of interest is insignificant. Financial instruments are classified into one of the following categories: amortized cost, fair value through earnings and fair value through other comprehensive income. The following table summarizes information regarding the carrying value of the Company’s financial instruments: (in thousands) June 30, December 31, Financial assets measured at amortized cost: Cash and cash equivalents $ 38,447 $ 48,419 Accounts receivable 126,145 121,525 $ 164,592 $ 169,944 Financial liabilities measured at amortized cost: Accounts payable $ 33,787 $ 34,326 Current portion of long-term debt 16,299 14,789 Current portion of leases 26,094 27,254 Non-current portion of long-term debt 1,220,823 1,197,596 Non-current portion of leases 184,916 200,326 Accrued liabilities 90,916 87,813 $ 1,572,835 $ 1,562,104 Financial liabilities measured at fair value through earnings: Derivative in subordinated notes $ 6,683 $ 7,522 Financial assets measured at fair value through other comprehensive income: Interest rate contracts $ 39 $ 3 Financial liabilities measured at fair value through other comprehensive income: Interest rate contracts $ — $ 53 Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis The Company measures certain non-financial assets at fair value on a nonrecurring basis, primarily intangible assets, goodwill and long-lived assets in connection with acquisitions and periodic evaluations for potential impairment. The Company estimates the fair value of these assets using primarily unobservable inputs; therefore, these are considered Level 3 fair value measurements. Interest Rate Risk

Stock-Based Awards

Stock-Based Awards	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Awards	Stock-Based Awards The Company may grant stock-based awards to employees, directors and consultants under the Amended and Restated Restricted Share Unit Plan, adopted as of November 14, 2017 (the “RSU Plan”) and the Amended and Restated Stock Option Plan, adopted as of November 14, 2017 (the “Stock Option Plan” and together with the RSU Plan, the “2017 Stock Plans”). Under the 2017 Stock Plans, the collective maximum number of shares reserved for issuance is equal to 10% of the number of capital shares of the Company that are outstanding from time to time. As of June 30, 2022 and December 31, 2021, common shares reserved for issuance under the 2017 Stock Plans were 8,951,651 and 8,902,699 respectively. The 2017 Stock Plans are administered by the Board of Directors, which has authority to select eligible persons to receive awards and to determine the terms and conditions of the awards. Restricted Share Units Restricted share units (“RSUs”) represent a right to receive a share of common stock at a future vesting date with no cash payment from the holder. RSUs granted generally vest over 2 years from the date of grant. A summary of RSU activity is as follows: Number of Weighted- Aggregate Grant Date Outstanding and unvested at December 31, 2021 2,029,032 $ 2.41 Granted 799,085 1.10 $ 875 Vested (489,516) 3.19 $ 1,561 Outstanding and unvested at June 30, 2022 2,338,601 $ 1.80 $ 4,210 Stock Options Stock options are awarded as consideration in exchange for services rendered to the Company. Stock options granted generally have terms of 7 to 10 years and vest over 3 years. A summary of the stock option activity is as follows: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2021 5,680,120 $ 2.54 4.4 $ 2,344 Outstanding at June 30, 2022 5,668,120 $ 2.53 3.8 $ 188 Exercisable at June 30, 2022 5,072,519 $ 2.44 3.7 $ 188 Aggregate intrinsic value for outstanding and exercisable stock options in the table above represents the difference between the closing stock price on June 30, 2022 and the exercise price multiplied by the number of in-the-money options. No stock options were granted during the six months ended June 30, 2022.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments The Company has certain binding purchase commitments primarily for the purchase of equipment from various suppliers. As of June 30, 2022, the obligations for these future purchase commitments totaled $46.6 million, of which $36.0 million is expected to be paid during the remaining six months of 2022 and $10.6 million is expected to be paid thereafter. Guarantees and Indemnities In the normal course of business, the Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. The Company indemnifies other parties, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed to hold the other party harmless against losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims arising from a breach of representations or covenants. In addition, the Company has entered into indemnification agreements with its executive officers and directors and the Company’s bylaws contain similar indemnification obligations. Under these arrangements, the Company is obligated to indemnify, to the fullest extent permitted under applicable law, its current or former officers and directors for various amounts incurred with respect to actions, suits or proceedings in which they were made, or threatened to be made, a party as a result of acting as an officer or director. It is not possible to determine the maximum potential amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. Historically, payments made related to these indemnifications have been immaterial. As of June 30, 2022, the Company has determined that no liability is necessary related to these guarantees and indemnities. Legal Matters On November 22, 2021, an alleged shareholder of the Company filed a putative class action claim with the Ontario Superior Court of Justice against the Company and certain of its directors and officers alleging violations of Securities Act (Ontario), negligent misrepresentation and other related claims. The claims generally allege that certain of the Company’s prior public financial statements misrepresented the Company’s revenue, accounts receivable and the value of its assets based upon the Company’s August 12, 2021, October 12, 2021 and November 8, 2021 disclosures relating to a review of certain procedures related to its financial statements and to the restatement of financial statements affecting accounts receivable and net book value of property and equipment. The claim does not quantify a damage request. Defendants have not yet responded to the claim. On December 20, 2021, a second statement of claim was filed by a new plaintiff making similar allegations. Because the two statements of claim involve similar subject matter and some of the same class members, the second Ontario plaintiff firm requested a motion for carriage under the Class Proceedings Act, 1992 (Ontario) so the court could determine which plaintiff firm will have carriage of the class action proceedings. That carriage motion was heard by the court on March 31, 2022 and, on April 27, 2022, the court rendered a decision in favor of the second plaintiff. As such, the second plaintiff has been awarded carriage of the class action claim and the action by the first plaintiff is stayed. Other Matters

Supplemental Revenue Informatio

Supplemental Revenue Information	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Supplemental Revenue Information	Supplemental Revenue Information Revenues consist primarily of net patient fees received from various payors and patients based on established contractual billing rates, less allowances for contractual adjustments and implicit price concessions. Revenues are also derived directly from hospitals and healthcare providers. Other revenue consists of miscellaneous fees under contractual arrangements, including service fee revenue under capitation arrangements with third-party payors, management fees, government grants and fees for other services provided to third parties. The following table summarizes the components of the Company’s revenues by payor category: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Patient fee payors: Commercial $ 71,609 $ 54,803 $ 140,710 $ 105,602 Medicare 21,002 8,806 42,174 16,990 Medicaid 3,347 2,026 6,449 3,857 Other patient revenue 3,213 2,608 6,487 5,260 99,171 68,243 195,820 131,709 Hospitals and healthcare providers 90,651 — 178,110 — Other revenue 2,306 1,253 4,461 1,750 $ 192,128 $ 69,496 $ 378,391 $ 133,459

Cost of Operations, excluding D

Cost of Operations, excluding Depreciation and Amortization	6 Months Ended
	Jun. 30, 2022
Cost Of Operations Excluding Depreciation And Amortization [Abstract]
Cost of Operations, excluding Depreciation and Amortization	Cost of Operations, excluding Depreciation and Amortization The following table summarizes the components of the Company’s cost of operations, excluding depreciation and amortization: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Employee compensation $ 72,021 $ 23,792 $ 147,148 $ 46,910 Third-party services and professional fees 29,919 7,758 59,096 14,617 Rent and utilities 12,742 7,662 25,219 15,346 Reading fees 11,788 10,860 23,286 20,844 Administrative 11,467 4,829 23,091 9,185 Medical supplies and other 16,637 2,867 31,895 6,008 $ 154,574 $ 57,768 $ 309,735 $ 112,910

Supplemental Statement of Opera

Supplemental Statement of Operations Information	6 Months Ended
	Jun. 30, 2022
Other Income and Expenses [Abstract]
Supplemental Statement of Operations Information	Supplemental Statement of Operations Information Restructuring Charges Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Transformation costs $ 4,025 $ — $ 4,025 $ — Lease termination costs 1,840 — 1,840 — Domestication and related costs 1,063 — 1,063 — Other 316 — 396 — $ 7,244 $ — $ 7,324 $ — Transformation costs consist of third-party consulting fees associated with a significant project to identify, plan, and implement various business improvement initiatives designed to enhance growth opportunities and improve operations. The project is expected to continue into 2024. The consulting agreement provides for fixed fees totaling $12.5 million, milestone fees totaling up to $7.0 million that are earned upon the achievement of certain milestones, and performance fees totaling up to $15.0 million that are earned based on the achievement of certain performance results during the period of the contract. The Company recognizes the fixed fees over the contract period as the services are rendered. Milestone and performance fees that are probable of ultimately being paid are recognized based on a percentage of achievement of the related milestone or performance result. As of June 30, 2022, the accrued liability for unpaid transformation consulting costs was $2.8 million. Lease termination costs relate to a $1.8 million payment made in May 2022 pursuant to an agreement to early terminate the lease for one of the Company’s office facilities. In addition, the Company derecognized $3.2 million for the related operating lease right-of-use asset and the associated lease liability during the three months ended June 30, 2022. Domestication and related costs consist of professional fees incurred related to the change in the Company’s jurisdiction of incorporation from the province of Ontario (Canada) to the State of Delaware (USA). This change in jurisdiction was approved by the shareholders in June 2022 and is expected to be completed by late 2022. Severance and Related Costs Severance and related costs represent costs associated with employees whose employment with the Company has been terminated and are generally paid in the year recorded. During the six months ended June 30, 2022, the Company implemented a small workforce reduction and recorded severance and related costs. In connection with certain terminated employees, severance benefits are being paid over periods of 12 to 18 months. As of June 30, 2022, the unpaid balance of severance and related costs totaled $6.3 million, of which $5.6 million will be paid during the next twelve months and the remaining $0.7 million will be paid thereafter. Other Operating and Non-Operating Expense (Income) Other operating expense, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Loss on disposal of property and equipment, net $ 170 $ 255 $ 372 $ 346 Other, net 416 — 207 — $ 586 $ 255 $ 579 $ 346 Other non-operating income, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Fair value adjustment on derivative in subordinated notes $ (1,009) $ — $ (839) $ — Earnings from unconsolidated investees (248) — (488) — Gain on conversion of debt to equity investment (Note 17) — — — (3,360) Other, net (1,164) — (1,152) (6) $ (2,421) $ — $ (2,479) $ (3,366)

Investment in Unconsolidated In

Investment in Unconsolidated Investees	6 Months Ended
	Jun. 30, 2022
Other Investments [Abstract]
Investments in Unconsolidated Investees	Investments in Unconsolidated Investees Effective March 1, 2021, the Company completed a common equity investment in an artificial intelligence business (“AI business”) as part of a private placement offering for $4.6 million. The AI business develops artificial intelligence aided software programs for use in medical businesses, including outpatient imaging services provided by the Company. As a result of the investment, a previous investment in a convertible note instrument issued by the AI business to the Company in May 2020 converted to common equity. Upon conversion, the Company’s total common equity investment was estimated to be valued at $7.9 million and represented a 34.5% interest in the AI business on a non-diluted basis. In addition, the Company holds share purchase warrants which, subject to the occurrence of certain events and certain assumptions, and the payment of $0.4 million, would entitle the Company to acquire an additional 2.4% ownership interest in the AI business common equity. During the six months ended June 30, 2021, the Company recognized a gain of $3.4 million on the conversion of the convertible note instrument to common equity and the share purchase warrants. This gain is included in other non-operating income, net in the condensed consolidated statements of operations and comprehensive loss. The Company has a 15% direct ownership in an unconsolidated investee and provides management services under a management agreement with the investee. The Company provides services as part of its ongoing operations for and on behalf of the unconsolidated investee, which reimburses the Company for the actual amount of the expenses incurred. The Company records the expenses in cost of operations and the reimbursement as revenue in the condensed consolidated statement of operations and comprehensive loss.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate for the three and six months ended June 30, 2022 and 2021 differs from the Canadian statutory rate of 26.5% primarily due to earnings in foreign jurisdictions that are subject to tax rates which differ from the Canadian statutory tax rate, as well as the impact of valuation allowances applied against losses in jurisdictions for which no tax benefit or expense is recognized.

Basic and Diluted Loss per Shar

Basic and Diluted Loss per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share The loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average common shares outstanding during the period. Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2022 2021 2022 2021 Net loss attributable to common shareholders $ (30,469) $ (7,356) $ (61,280) $ (10,233) Weighted average common shares outstanding: Basic and diluted 89,516,513 70,846,010 89,296,619 70,514,063 Net loss per share attributable to common shareholders: Basic and diluted $ (0.34) $ (0.10) $ (0.69) $ (0.15) Employee stock options, warrants and restricted share units excluded from the computation of diluted per share amounts as their effect would be antidilutive 2,042,461 1,803,349 2,207,983 1,820,926

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer. Prior to the Alliance Acquisition, the Company had one reportable segment, which was outpatient diagnostic imaging services. As a result of the acquisition, the Company operates in two reportable segments: Radiology and Oncology. All intercompany revenues, expenses, payables and receivables are eliminated in consolidation and are not reviewed when evaluating segment performance. Each segment’s performance is evaluated based on revenue and earnings before interest, income taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA. The following table summarizes the Company’s revenues by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Radiology $ 160,867 $ 69,496 $ 316,207 $ 133,459 Oncology 31,261 — 62,184 — $ 192,128 $ 69,496 $ 378,391 $ 133,459 Adjusted EBITDA is defined as net income before interest expense, income tax expense (benefit), depreciation and amortization, restructuring charges, severance and related costs, settlements and related costs (recoveries), stock-based compensation, losses (gains) on disposal of property and equipment, acquisition-related costs, financial instrument revaluation adjustments, gain on conversion of debt to equity investment, deferred rent expense, impairment charges, other losses (gains), and one-time adjustments. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities, or other financial statement data presented in the condensed consolidated financial statements as an indicator of financial performance or liquidity. Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation and may not be comparable to other similarly titled measures of other companies. Adjusted EBITDA is the most frequently used measure of each segment’s performance and is commonly used in setting performance goals. The following table summarizes the Company’s Adjusted EBITDA by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Adjusted EBITDA: Radiology $ 35,692 $ 14,346 $ 64,281 $ 25,189 Oncology 10,302 — 20,335 — Corporate (7,810) (2,136) (14,414) (3,776) $ 38,184 $ 12,210 $ 70,202 $ 21,413 A reconciliation of the net loss to total Adjusted EBITDA is shown below: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Net loss $ (26,079) $ (6,854) $ (52,511) $ (9,362) Interest expense 29,290 8,920 57,971 17,288 Income tax expense (benefit) (3,483) 6 (2,920) 71 Depreciation and amortization 25,200 4,584 49,931 9,073 EBITDA 24,928 6,656 52,471 17,070 Adjustments: Restructuring charges 7,244 — 7,324 — Severance and related costs 5,559 — 7,797 — Settlements, recoveries and related costs 814 (318) 677 (341) Stock-based compensation 758 785 1,819 1,212 Loss on disposal of property and equipment, net 170 255 372 346 Acquisition-related costs 86 4,350 468 5,628 Fair value adjustment on derivative (1,009) — (839) — Gain on conversion of debt to equity investment — — — (3,360) Deferred rent expense 247 459 579 904 Other, net (613) 23 (466) (46) Adjusted EBITDA $ 38,184 $ 12,210 $ 70,202 $ 21,413 The following table summarizes the Company’s total assets by segment: (in thousands) June 30, December 31, Identifiable assets: Radiology $ 1,417,348 $ 1,451,905 Oncology 424,374 440,416 Corporate 19,771 26,505 $ 1,861,493 $ 1,918,826 The following table summarizes the Company’s capital expenditures by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Capital expenditures: Radiology $ 4,648 $ 1,411 $ 13,460 $ 2,584 Oncology 858 — 1,834 — Corporate 82 — 172 — $ 5,588 $ 1,411 $ 15,466 $ 2,584

New Accounting Standards (Polic

New Accounting Standards (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recently Adopted Standards and Standards Not Yet Effective	Recently Adopted Accounting Standards ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) In April 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This guidance clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options due to a lack of explicit guidance in the FASB Codification. This ASU is effective for all entities for fiscal years beginning after December 15, 2021. The Company adopted this standard as of January 1, 2022 and it did not have a material impact on the Company’s condensed consolidated financial statements. ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance , which aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. ASU 2021-10 also adds a new Topic—ASC 832, Government Assistance —to the FASB’s Codification. The disclosure requirements only apply to transactions with a government that are accounted for by analogizing to either a grant model or a contribution model. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this standard as of January 1, 2022 and it did not have a material impact on the Company’s condensed consolidated financial statements. Recently Issued Accounting Standards Not Yet Effective ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , and related clarifying standards, which replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to assess credit loss estimates. This ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. For all other entities, this ASU is effective for fiscal years beginning after December 15, 2022. The Company is considered an Emerging Growth Company as classified by the Securities and Exchange Commission (“SEC”), which gives the Company relief in the timing of implementation of this standard by allowing the private company timing for adoption. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedients and exceptions for applying generally accepted accounting principles to certain contract modifications and hedging relationships that reference London Inter-bank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued. For all entities, the guidance is effective upon issuance and generally can be applied through December 31, 2022. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2021-01, Reference Rate Reform (Topic 848): Scope In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope . This ASU clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain option expedients and exceptions in Topic 848. The guidance is effective upon issuance and generally can be applied through December 31, 2022. The Company is currently evaluating the impact of the standard on its consolidated financial statements. ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805) In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , creating an exception to the recognition and measurement principles in ASC 805, Business Combinations . The amendments require an acquirer to use the guidance in ASC 606, Revenue from Contracts with Customers , rather than using fair value, when recognizing and measuring contract assets and contract liabilities related to customer contracts assumed in a business combination. In addition, the amendments clarify that all contracts requiring the recognition of assets and liabilities in accordance with the guidance in ASC 606, such as contract liabilities derived from the sale of nonfinancial assets within the scope of ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets

Alliance Acquisition (Tables)

Alliance Acquisition (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of the Fair Value Determination of the Acquired Assets and Assumed Liabilities	The following table summarizes the revised preliminary assessment of fair value of the assets acquired and liabilities assumed as of the date of the acquisition: (in thousands) Assets acquired: Cash and cash equivalents $ 26,125 Net working capital 14,221 Property and equipment 205,940 Operating lease right-of-use assets 69,919 Goodwill 456,195 Intangibles – Customer contracts 266,224 Intangibles – Trade names 69,108 Intangibles – Third party management agreements 10,200 Intangibles – Certificates of need 69,558 Other assets 8,170 1,195,660 Liabilities assumed: Equipment debt 54,539 Obligations under finance leases 9,041 Obligations under operating leases 74,290 Deferred tax liabilities 52,760 Other liabilities 7,234 197,864 Net assets acquired 997,796 Less redeemable noncontrolling interests 37,040 Less noncontrolling interests 175,140 Purchase price $ 785,616

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of Detailed Information of Property and Equipment	Property and equipment consists of the following: (in thousands) June 30, December 31, Medical equipment $ 236,007 $ 227,796 Leasehold improvements 41,274 39,763 Equipment under finance leases 35,574 34,597 Office and computer equipment 19,246 16,701 Transportation and service equipment 11,672 8,996 Furniture and fixtures 3,399 3,130 Construction in progress 1,186 6,423 348,358 337,406 Less accumulated depreciation 117,061 78,284 $ 231,297 $ 259,122

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill are as follows: (in thousands) Radiology Oncology Total Balance, December 31, 2021 $ 681,993 $ 158,360 $ 840,353 Adjustments 360 75 435 Balance, June 30, 2022 $ 682,353 $ 158,435 $ 840,788

Other Intangible Assets - (Tabl

Other Intangible Assets - (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule Of Intangible Assets Excluding Goodwill	Other intangible assets consist of the following: (dollars in thousands) Weighted June 30, 2022 December 31, 2021 Gross Accumulated Other Gross Accumulated Other Finite-lived intangible assets: Customer contracts 20 $ 266,059 $ (11,116) $ 254,943 $ 266,224 $ (4,437) $ 261,787 Trade names 18 77,466 (8,618) 68,848 77,466 (6,054) 71,412 Management agreements 17 10,200 (500) 9,700 10,200 (200) 10,000 Other 4 4,814 (3,883) 931 4,814 (3,425) 1,389 Total $ 358,539 $ (24,117) 334,422 $ 358,704 $ (14,116) 344,588 Certificates of Need 69,558 69,558 Total other intangible assets $ 403,980 $ 414,146

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt consists of the following: (in thousands) June 30, December 31, 2028 Senior Notes $ 375,000 $ 375,000 2025 Senior Notes 475,000 475,000 Subordinated Notes 397,074 372,470 Equipment Debt 60,212 58,827 1,307,286 1,281,297 Debt discount and deferred issuance costs (70,164) (68,912) 1,237,122 1,212,385 Less current portion 16,299 14,789 Long-term debt, net of current portion $ 1,220,823 $ 1,197,596

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of Other Accrued Liabilities	Accrued liabilities consist of the following: (in thousands) June 30, December 31, Accrued compensation and related expenses $ 35,525 $ 26,486 Accrued interest expense 17,823 16,840 Other 37,568 44,487 $ 90,916 $ 87,813

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Summary of Redeemable Noncontrolling Interests	The following is a rollforward of the activity in the redeemable noncontrolling interests for the six months ended June 30, 2022: (in thousands) Balance, December 31, 2021 $ 37,469 Net income attributable to redeemable noncontrolling interests 1,114 Distributions paid to redeemable noncontrolling interests (2,541) Balance, June 30, 2022 $ 36,042

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Instruments [Abstract]
Schedule of Fair Value Measurements, Recurring and Nonrecurring	The following table summarizes the valuation of the Company’s financial instruments that are reported at fair value on a recurring basis: Fair Value as of June 30, 2022 Fair Value as of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Current and long-term assets: Interest rate contracts $ — $ 39 $ — $ 39 $ — $ 3 $ — $ 3 Current and long-term liabilities: Derivative in subordinated notes $ — $ — $ 6,683 $ 6,683 $ — $ — $ 7,522 $ 7,522 Interest rate contracts $ — $ — $ — $ — $ — $ 53 $ — $ 53
Summary of Reconciliation of Liability Related to the Embedded Derivative	The following is a reconciliation of the opening and closing balances for the liability related to the embedded derivative included in the Subordinated Notes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 30, 2022: (in thousands) Balance, December 31, 2021 $ 7,522 Change in fair value (839) Balance, June 30, 2022 $ 6,683
Schedule Of Fair Value Of Other Current And Non Current Liabilities	The estimated fair values of other current and non-current liabilities are as follows: (in thousands) June 30, December 31, 2028 Senior Notes $ 264,375 $ 345,938 2025 Senior Notes 365,750 446,500 Subordinated Notes 249,197 323,620 Equipment Debt 51,862 56,879 $ 931,184 $ 1,172,937
Schedule of Information Regarding The Carrying Value Of Financial Instruments	The following table summarizes information regarding the carrying value of the Company’s financial instruments: (in thousands) June 30, December 31, Financial assets measured at amortized cost: Cash and cash equivalents $ 38,447 $ 48,419 Accounts receivable 126,145 121,525 $ 164,592 $ 169,944 Financial liabilities measured at amortized cost: Accounts payable $ 33,787 $ 34,326 Current portion of long-term debt 16,299 14,789 Current portion of leases 26,094 27,254 Non-current portion of long-term debt 1,220,823 1,197,596 Non-current portion of leases 184,916 200,326 Accrued liabilities 90,916 87,813 $ 1,572,835 $ 1,562,104 Financial liabilities measured at fair value through earnings: Derivative in subordinated notes $ 6,683 $ 7,522 Financial assets measured at fair value through other comprehensive income: Interest rate contracts $ 39 $ 3 Financial liabilities measured at fair value through other comprehensive income: Interest rate contracts $ — $ 53

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of RSU Activity	Restricted share units (“RSUs”) represent a right to receive a share of common stock at a future vesting date with no cash payment from the holder. RSUs granted generally vest over 2 years from the date of grant. A summary of RSU activity is as follows: Number of Weighted- Aggregate Grant Date Outstanding and unvested at December 31, 2021 2,029,032 $ 2.41 Granted 799,085 1.10 $ 875 Vested (489,516) 3.19 $ 1,561 Outstanding and unvested at June 30, 2022 2,338,601 $ 1.80 $ 4,210
Summary of the Stock Option Activity	A summary of the stock option activity is as follows: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2021 5,680,120 $ 2.54 4.4 $ 2,344 Outstanding at June 30, 2022 5,668,120 $ 2.53 3.8 $ 188 Exercisable at June 30, 2022 5,072,519 $ 2.44 3.7 $ 188

Supplemental Revenue Informat_2

Supplemental Revenue Information (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Revenue Information	The following table summarizes the components of the Company’s revenues by payor category: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Patient fee payors: Commercial $ 71,609 $ 54,803 $ 140,710 $ 105,602 Medicare 21,002 8,806 42,174 16,990 Medicaid 3,347 2,026 6,449 3,857 Other patient revenue 3,213 2,608 6,487 5,260 99,171 68,243 195,820 131,709 Hospitals and healthcare providers 90,651 — 178,110 — Other revenue 2,306 1,253 4,461 1,750 $ 192,128 $ 69,496 $ 378,391 $ 133,459

Cost of Operations, excluding_2

Cost of Operations, excluding Depreciation and Amortization (Tables)	6 Months Ended
	Jun. 30, 2022
Cost Of Operations Excluding Depreciation And Amortization [Abstract]
Summary of Cost Of Goods And Service Excluding Depletion Depreciation And Amortization	The following table summarizes the components of the Company’s cost of operations, excluding depreciation and amortization: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Employee compensation $ 72,021 $ 23,792 $ 147,148 $ 46,910 Third-party services and professional fees 29,919 7,758 59,096 14,617 Rent and utilities 12,742 7,662 25,219 15,346 Reading fees 11,788 10,860 23,286 20,844 Administrative 11,467 4,829 23,091 9,185 Medical supplies and other 16,637 2,867 31,895 6,008 $ 154,574 $ 57,768 $ 309,735 $ 112,910

Supplemental Statement of Ope_2

Supplemental Statement of Operations Information (Tables)	6 Months Ended
	Jun. 30, 2022
Other Income and Expenses [Abstract]
Schedule of Restructuring Charges	Restructuring Charges Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Transformation costs $ 4,025 $ — $ 4,025 $ — Lease termination costs 1,840 — 1,840 — Domestication and related costs 1,063 — 1,063 — Other 316 — 396 — $ 7,244 $ — $ 7,324 $ —
Schedule of Other Operating Losses (gains)	Other operating expense, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Loss on disposal of property and equipment, net $ 170 $ 255 $ 372 $ 346 Other, net 416 — 207 — $ 586 $ 255 $ 579 $ 346
Schedule Of Other Non-operating Losses (gains)	Other non-operating income, net consists of the following: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Fair value adjustment on derivative in subordinated notes $ (1,009) $ — $ (839) $ — Earnings from unconsolidated investees (248) — (488) — Gain on conversion of debt to equity investment (Note 17) — — — (3,360) Other, net (1,164) — (1,152) (6) $ (2,421) $ — $ (2,479) $ (3,366)

Basic and Diluted Loss per Sh_2

Basic and Diluted Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary Of Earnings Per Share Basic And Diluted	The loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted average common shares outstanding during the period. Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2022 2021 2022 2021 Net loss attributable to common shareholders $ (30,469) $ (7,356) $ (61,280) $ (10,233) Weighted average common shares outstanding: Basic and diluted 89,516,513 70,846,010 89,296,619 70,514,063 Net loss per share attributable to common shareholders: Basic and diluted $ (0.34) $ (0.10) $ (0.69) $ (0.15) Employee stock options, warrants and restricted share units excluded from the computation of diluted per share amounts as their effect would be antidilutive 2,042,461 1,803,349 2,207,983 1,820,926

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Summary Of Revenue By Segment	The following table summarizes the Company’s revenues by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Radiology $ 160,867 $ 69,496 $ 316,207 $ 133,459 Oncology 31,261 — 62,184 — $ 192,128 $ 69,496 $ 378,391 $ 133,459
Summary Of Company's Adjusted EBITDA	The following table summarizes the Company’s Adjusted EBITDA by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Adjusted EBITDA: Radiology $ 35,692 $ 14,346 $ 64,281 $ 25,189 Oncology 10,302 — 20,335 — Corporate (7,810) (2,136) (14,414) (3,776) $ 38,184 $ 12,210 $ 70,202 $ 21,413
Summary of Net Income (Loss) to Total Adjusted EBITDA	A reconciliation of the net loss to total Adjusted EBITDA is shown below: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Net loss $ (26,079) $ (6,854) $ (52,511) $ (9,362) Interest expense 29,290 8,920 57,971 17,288 Income tax expense (benefit) (3,483) 6 (2,920) 71 Depreciation and amortization 25,200 4,584 49,931 9,073 EBITDA 24,928 6,656 52,471 17,070 Adjustments: Restructuring charges 7,244 — 7,324 — Severance and related costs 5,559 — 7,797 — Settlements, recoveries and related costs 814 (318) 677 (341) Stock-based compensation 758 785 1,819 1,212 Loss on disposal of property and equipment, net 170 255 372 346 Acquisition-related costs 86 4,350 468 5,628 Fair value adjustment on derivative (1,009) — (839) — Gain on conversion of debt to equity investment — — — (3,360) Deferred rent expense 247 459 579 904 Other, net (613) 23 (466) (46) Adjusted EBITDA $ 38,184 $ 12,210 $ 70,202 $ 21,413
Schedule Of Segment Reporting Information By Segment	The following table summarizes the Company’s total assets by segment: (in thousands) June 30, December 31, Identifiable assets: Radiology $ 1,417,348 $ 1,451,905 Oncology 424,374 440,416 Corporate 19,771 26,505 $ 1,861,493 $ 1,918,826 The following table summarizes the Company’s capital expenditures by segment: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2022 2021 2022 2021 Capital expenditures: Radiology $ 4,648 $ 1,411 $ 13,460 $ 2,584 Oncology 858 — 1,834 — Corporate 82 — 172 — $ 5,588 $ 1,411 $ 15,466 $ 2,584

Alliance Acquisition - Addition

Alliance Acquisition - Additional information (Detail) - Alliance Acquisition - USD ($) $ in Millions		6 Months Ended
	Sep. 01, 2021	Jun. 30, 2022
Alliance Acquisition
Business acquisition, percentage of voting interests acquired	100%
Purchase price	$ 785.6
Fair value of interests in joint ventures	$ 212
Decrease in property and equipment acquired		$ 0.5
Decrease in other liabilities acquired		0.1
Decrease in obligations under finance leases		0.1
Increase in noncontrolling interest acquired		0.2
Increase in goodwill		$ 0.4

Alliance Acquisition - Summary

Alliance Acquisition - Summary of the Fair Value Determination of the Acquired Assets and Assumed Liabilities as Follows (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Sep. 01, 2021
Assets acquired
Goodwill	$ 840,788	$ 840,353
Alliance Acquisition
Assets acquired
Cash and cash equivalents			$ 26,125
Net working capital			14,221
Property and equipment			205,940
Operating lease right-of-use assets			69,919
Goodwill			456,195
Other assets			8,170
Assets			1,195,660
Current liabilities
Equipment debt			54,539
Obligations under finance leases			9,041
Non-current liabilities
Obligations under operating leases			74,290
Deferred tax liabilities			52,760
Other liabilities			7,234
Liabilities			197,864
Net assets acquired			997,796
Less redeemable noncontrolling interests			37,040
Less noncontrolling interests			175,140
Purchase price			785,616
Alliance Acquisition | Customer contracts
Assets acquired
Intangible assets			266,224
Alliance Acquisition | Trade names
Assets acquired
Intangible assets			69,108
Alliance Acquisition | Third party management agreements
Assets acquired
Intangible assets			10,200
Alliance Acquisition | Certificates of need
Assets acquired
Intangible assets			$ 69,558

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Variable Interest Entity [Line Items]
Assets	$ 1,861,493		$ 1,918,826
Liabilities	1,604,959		1,597,678
Net cash provided by operating activities	21,079	$ 2,761
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Assets	23,400		20,400
Liabilities	0		$ 600
Revenues	92,800	83,300
Net cash provided by operating activities	$ 93,200	$ 90,200

Property and Equipment - Summar

Property and Equipment - Summary of Detailed Information of Property and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Equipment under finance leases	$ 35,574	$ 34,597
Total property and equipment, gross	348,358	337,406
Less accumulated depreciation	117,061	78,284
Property and equipment, net	231,297	259,122
Medical equipment
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	236,007	227,796
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	41,274	39,763
Office and computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	19,246	16,701
Transportation and service equipment
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	11,672	8,996
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	3,399	3,130
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment – cost	$ 1,186	$ 6,423

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 20.2	$ 3.9	$ 39.9	$ 7.7
Net book value of equipment under finance leases	$ 20.7		$ 20.7		$ 22.2

Goodwill - Schedule of Goodwill

Goodwill - Schedule of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2021	$ 840,353
Adjustments	435
Balance, June 30, 2022	840,788
Radiology
Goodwill [Roll Forward]
Balance, December 31, 2021	681,993
Adjustments	360
Balance, June 30, 2022	682,353
Oncology
Goodwill [Roll Forward]
Balance, December 31, 2021	158,360
Adjustments	75
Balance, June 30, 2022	$ 158,435

Other Intangible Assets - Sched

Other Intangible Assets - Schedule Of Intangible Assets Excluding Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 358,539	$ 358,704
Accumulated Amortization	(24,117)	(14,116)
Other Intangible Assets, Net	334,422	344,588
Certificates of Need	69,558	69,558
Total other intangible assets	$ 403,980	414,146
Customer contracts
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	20 years
Gross Carrying Amount	$ 266,059	266,224
Accumulated Amortization	(11,116)	(4,437)
Other Intangible Assets, Net	$ 254,943	261,787
Trade names
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	18 years
Gross Carrying Amount	$ 77,466	77,466
Accumulated Amortization	(8,618)	(6,054)
Other Intangible Assets, Net	$ 68,848	71,412
Management agreements
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	17 years
Gross Carrying Amount	$ 10,200	10,200
Accumulated Amortization	(500)	(200)
Other Intangible Assets, Net	$ 9,700	10,000
Other
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (in years)	4 years
Gross Carrying Amount	$ 4,814	4,814
Accumulated Amortization	(3,883)	(3,425)
Other Intangible Assets, Net	$ 931	$ 1,389

Other Intangible Assets - Addit

Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of finite-lived intangible assets	$ 5	$ 0.7	$ 10	$ 1.4

Long-Term Debt - Summary of Lon

Long-Term Debt - Summary of Long-term debt (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Disclosure Details Of Allocation Of Gross Proceeds From Subordinated Debt Shares Warrants and Derivatives [Line Items]
Long-term debt	$ 1,307,286	$ 1,281,297
Debt discount and deferred issuance costs	(70,164)	(68,912)
Total long-term debt	1,237,122	1,212,385
Current portion of long-term debt	16,299	14,789
Long-term debt, net of current portion	1,220,823	1,197,596
2028 Senior Notes
Disclosure Details Of Allocation Of Gross Proceeds From Subordinated Debt Shares Warrants and Derivatives [Line Items]
Long-term debt	375,000	375,000
2025 Senior Notes
Disclosure Details Of Allocation Of Gross Proceeds From Subordinated Debt Shares Warrants and Derivatives [Line Items]
Long-term debt	475,000	475,000
Subordinated Notes
Disclosure Details Of Allocation Of Gross Proceeds From Subordinated Debt Shares Warrants and Derivatives [Line Items]
Long-term debt	397,074	372,470
Equipment Debt
Disclosure Details Of Allocation Of Gross Proceeds From Subordinated Debt Shares Warrants and Derivatives [Line Items]
Long-term debt	$ 60,212	$ 58,827

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Subordinated Notes
Debt Instrument [Line Items]
Accrued interest added to the principal balance	$ 24.6

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued compensation and related expenses	$ 35,525	$ 26,486
Accrued interest expense	17,823	16,840
Other	37,568	44,487
Total other accrued liabilities	$ 90,916	$ 87,813

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Noncontrolling Interest [Abstract]
Redeemable noncontrolling interests	$ 36,042	$ 37,469

Redeemable Noncontrolling Int_4

Redeemable Noncontrolling Interest - Summary of Redeemable Noncontrolling Interests (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance, December 31, 2021	$ 37,469
Net income attributable to redeemable noncontrolling interests	1,114
Distributions paid to redeemable noncontrolling interests	(2,541)
Balance, June 30, 2022	$ 36,042

Financial Instruments - Schedul

Financial Instruments - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Interest rate contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term assets	$ 39	$ 3
Current and long-term liabilities	0	53
Interest rate contracts | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term assets	0	0
Current and long-term liabilities	0	0
Interest rate contracts | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term assets	39	3
Current and long-term liabilities	0	53
Interest rate contracts | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term assets	0	0
Current and long-term liabilities	0	0
Derivative in subordinated notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term liabilities	6,683	7,522
Derivative in subordinated notes | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term liabilities	0	0
Derivative in subordinated notes | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term liabilities	0	0
Derivative in subordinated notes | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current and long-term liabilities	$ 6,683	$ 7,522

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) yr	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) yr	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) yr
Financial Instruments [Line Items]
Change in fair value	$ 1,009	$ 0	$ 839	$ 0
Level 3 | Stone Peak Magnet | Subordinated Notes
Financial Instruments [Line Items]
Change in fair value			$ 839
Level 3 | Measurement Input Probability Weighted Time
Financial Instruments [Line Items]
Embedded derivative liability measurment input | yr	3.9		3.9		4.2
Level 3 | Measurement Input Probability Of Exit Event Percentage
Financial Instruments [Line Items]
Embedded derivative liability measurment input	0.240		0.240		0.245
Equipment Debt
Financial Instruments [Line Items]
Long term debt unhedged	$ 1,400		$ 1,400		$ 1,800
Revolving Credit Facility | Interest Rate Contract
Financial Instruments [Line Items]
Increase decrease in the variable rate of interest	1%		1%		1%

Financial Instruments - Summary

Financial Instruments - Summary of Reconciliation of Liability Related to the Embedded Derivative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of Movement In Embedded Derivative Liabilities [Roll Forward]
Change in fair value	$ (1,009)	$ 0	$ (839)	$ 0
Subordinated Notes | Stone Peak Magnet | Level 3
Disclosure Of Movement In Embedded Derivative Liabilities [Roll Forward]
Balance, December 31, 2021			7,522
Change in fair value			(839)
Balance, June 30, 2022	$ 6,683		$ 6,683

Financial Instruments - Sched_2

Financial Instruments - Schedule Of Fair Value Of Other Current And Non Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument fair value	$ 931,184	$ 1,172,937
2028 Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument fair value	264,375	345,938
2025 Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument fair value	365,750	446,500
Subordinated Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument fair value	249,197	323,620
Equipment Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument fair value	$ 51,862	$ 56,879

Financial Instruments - Sched_3

Financial Instruments - Schedule of Information Regarding The Carrying Value Of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 38,447	$ 48,419
Accounts receivable	126,145	121,525
Current portion of long-term debt	16,299	14,789
Long-term debt, net of current portion	1,220,823	1,197,596
Accrued liabilities	90,916	87,813
Reported Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	38,447	48,419
Accounts receivable	126,145	121,525
Financial assets measured at amortized cost	164,592	169,944
Accounts payable	33,787	34,326
Current portion of long-term debt	16,299	14,789
Current portion of leases	26,094	27,254
Long-term debt, net of current portion	1,220,823	1,197,596
Non-current portion of leases	184,916	200,326
Accrued liabilities	90,916	87,813
Financial liabilities measured at amortized cost	1,572,835	1,562,104
Financial liabilities measured at fair value through earnings:
Derivative in subordinated notes	6,683	7,522
Financial assets measured at fair value through other comprehensive income:
Interest rate contracts	39	3
Financial liabilities measured at fair value through other comprehensive income:
Interest rate contracts	$ 0	$ 53

Stock-Based Awards - Additional

Stock-Based Awards - Additional Information (Detail)		6 Months Ended
	Nov. 14, 2017	Jun. 30, 2022 shares	Dec. 31, 2021 shares
Restricted Stock Units (RSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		2 years
Employee Stock Option
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Vesting period		3 years
Options granted (in shares)		0
Employee Stock Option | Minimum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Term of award		7 years
Employee Stock Option | Maximum
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Term of award		10 years
2017 Stock Plans
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common stock options reserved for issuance (as a percent)	0.10
Common stock options reserved for issuance (in shares)		8,951,651	8,902,699

Stock-Based Awards - Summary of

Stock-Based Awards - Summary of RSU Activity (Detail) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Number of RSUs
Beginning balance (in shares) | shares	2,029,032
Granted (in shares) | shares	799,085
Vested (in shares) | shares	(489,516)
Ending balance (in shares) | shares	2,338,601
Weighted- Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 2.41
Granted (in dollars per share) | $ / shares	1.10
Vested (in dollars per share) | $ / shares	3.19
Ending balance (in dollars per share) | $ / shares	$ 1.80
Aggregate Grant Date Fair Value, Granted | $	$ 875
Aggregate Grant Date Fair Value, Vested | $	1,561
Aggregate Grant Date Fair Value, Outstanding and unvested | $	$ 4,210

Stock-Based Awards - Summary _2

Stock-Based Awards - Summary of the Stock Option Activity (Detail) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Number of Options
Beginning balance (in shares)	5,680,120
Ending balance (in shares)	5,668,120	5,680,120
Weighted- Average Exercise Price
Beginning balance (in dollars per share)	$ 2.54
Ending balance (in dollars per share)	$ 2.53	$ 2.54
Stock Options Additional Disclosures
Number of Options, Exercisable (in shares)	5,072,519
Weighted-Average Exercise price, Exercisable (in dollars per share)	$ 2.44
Weighted- Average Remaining Contractual Term (Years)	3 years 9 months 18 days	4 years 4 months 24 days
Weighted-Average Remaining Contractual Term, Exercisable	3 years 8 months 12 days
Aggregate Intrinsic Value (in thousands)	$ 188	$ 2,344
Aggregate Intrinsic Value, Exercisable	$ 188

Commitments and Contingencies (

Commitments and Contingencies (Details) - Commitement For The Purchase Of Equipment $ in Millions	Jun. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Purchase commitments	$ 46.6
Within Next Twelve Months
Loss Contingencies [Line Items]
Purchase commitments	36
Greater Than Twelve Months
Loss Contingencies [Line Items]
Purchase commitments	$ 10.6

Supplemental Revenue Informat_3

Supplemental Revenue Information - Summary of Revenue Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Other revenue	$ 2,306	$ 1,253	$ 4,461	$ 1,750
Total revenue	192,128	69,496	378,391	133,459
Sales Channel, Directly to Consumer
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	99,171	68,243	195,820	131,709
Commercial | Sales Channel, Directly to Consumer
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	71,609	54,803	140,710	105,602
Medicare | Sales Channel, Directly to Consumer
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	21,002	8,806	42,174	16,990
Medicaid | Sales Channel, Directly to Consumer
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	3,347	2,026	6,449	3,857
Other patient revenue | Sales Channel, Directly to Consumer
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	3,213	2,608	6,487	5,260
Hospitals and healthcare providers | Sales Channel, Through Intermediary
Disaggregation of Revenue [Line Items]
Service fees - net of allowances and discounts	$ 90,651	$ 0	$ 178,110	$ 0

Cost of Operations, excluding_3

Cost of Operations, excluding Depreciation and Amortization - Summary of Cost of Goods and Services Excluding Depletion Depreciation And Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	$ 154,574	$ 57,768	$ 309,735	$ 112,910
Employee compensation
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	72,021	23,792	147,148	46,910
Third-party services and professional fees
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	29,919	7,758	59,096	14,617
Rent and utilities
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	12,742	7,662	25,219	15,346
Reading fees
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	11,788	10,860	23,286	20,844
Administrative
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	11,467	4,829	23,091	9,185
Medical supplies and other
Cost Of Goods And Service Excluding Depletion Depreciation And Amortization [Line Items]
Cost of operations, excluding depreciation and amortization	$ 16,637	$ 2,867	$ 31,895	$ 6,008

Supplemental Statement of Ope_3

Supplemental Statement of Operations Information - Schedule of Restructuring Charges (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 7,244	$ 0	$ 7,324	$ 0
Transformation costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		4,025	0	4,025	0
Lease termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,800	1,840	0	1,840	0
Domestication and related costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges		1,063	0	1,063	0
Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 316	$ 0	$ 396	$ 0

Supplemental Statement of Ope_4

Supplemental Statement of Operations Information - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 7,244	$ 0	$ 7,324	$ 0
Lease liability derecognized		3,200
Operating right-of-use asset derecognized		3,200
Minimum
Restructuring Cost and Reserve [Line Items]
Severance benefits, payment period				12 months
Maximum
Restructuring Cost and Reserve [Line Items]
Severance benefits, payment period				18 months
Transformation costs
Restructuring Cost and Reserve [Line Items]
Accrued liability for unpaid transformation consulting costs		2,800		$ 2,800
Restructuring charges		4,025	0	4,025	0
Transformation Costs, Fixed Fees
Restructuring Cost and Reserve [Line Items]
Remaining transformation costs		12,500		12,500
Transformation Costs, Milestone Fees
Restructuring Cost and Reserve [Line Items]
Remaining transformation costs		7,000		7,000
Transformation Costs, Performance Fees
Restructuring Cost and Reserve [Line Items]
Remaining transformation costs		15,000		15,000
Lease termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,800	1,840	$ 0	1,840	$ 0
Employee Severance
Restructuring Cost and Reserve [Line Items]
Accrued liability for unpaid transformation consulting costs		6,300		6,300
Accrued liability for unpaid transformation consulting costs to be paid during the next twelve months		5,600		5,600
Accrued liability for unpaid transformation consulting costs to be paid thereafter		$ 700		$ 700

Supplemental Statement of Ope_5

Supplemental Statement of Operations Information - Schedule of Other Operating Expense (Income) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Other Income and Expenses [Abstract]
Loss on disposal of property and equipment, net	$ (170)	$ (255)	$ (372)	$ (346)
Other, net	416	0	207	0
Total other operating expense, net	$ 586	$ 255	$ 579	$ 346

Supplemental Statement of Ope_6

Supplemental Statement of Operations Information - Schedule Of Other Non-operating Losses (gains) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Other Income and Expenses [Abstract]
Fair value adjustment on derivative in subordinated notes	$ (1,009)	$ 0	$ (839)	$ 0
Earnings from unconsolidated investees	(248)	0	(488)	0
Gain on conversion of debt to equity investment	0	0	0	(3,360)
Other, net	(1,164)	0	(1,152)	(6)
Total other expense, net	$ (2,421)	$ 0	$ (2,479)	$ (3,366)

Investment in Unconsolidated _2

Investment in Unconsolidated Investees (Detail) - USD ($) $ in Millions		6 Months Ended
	Mar. 01, 2021	Jun. 30, 2021	Jun. 30, 2022
Other Investments [Line Items]
Payments to acquire Investments	$ 4.6
Equity method investments			$ 7.9
AI Business
Other Investments [Line Items]
Equity method investment, ownership percentage	34.50%		15%
Other Financial Instruments Revaluation and other (Gains) Losses
Other Investments [Line Items]
Gain (loss) on conversion of debt investments		$ 3.4
Common Equity | Share Purchase Warrants
Other Investments [Line Items]
Payments to acquire Investments	$ 0.4
Common Equity | Share Purchase Warrants | AI Business
Other Investments [Line Items]
Equity method investment, ownership percentage			2.40%

Basic and Diluted Loss per Sh_3

Basic and Diluted Loss per Share - Summary of Earnings Per Share Basic and Diluted (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss attributable to common shareholders	$ (30,469)	$ (7,356)	$ (61,280)	$ (10,233)
Weighted average common shares outstanding:
Basic (in shares)	89,516,513	70,846,010	89,296,619	70,514,063
Diluted (in shares)	89,516,513	70,846,010	89,296,619	70,514,063
Net loss per share attributable to common shareholders:
Basic (in dollars per share)	$ (0.34)	$ (0.10)	$ (0.69)	$ (0.15)
Diluted (in dollars per share)	$ (0.34)	$ (0.10)	$ (0.69)	$ (0.15)
Employee stock options, warrants and restricted share units excluded from the computation of diluted per share amounts as their effect would be antidilutive	2,042,461	1,803,349	2,207,983	1,820,926

Segment Information - Additiona

Segment Information - Additional Information (Details) - Segments		10 Months Ended
	Aug. 31, 2021	Jun. 30, 2022
Segment Reporting [Abstract]
Number of reportable segments	1	2

Segment Information - Summary o

Segment Information - Summary of Company's Revenues By Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 192,128	$ 69,496	$ 378,391	$ 133,459
Radiology
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	160,867	69,496	316,207	133,459
Oncology
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 31,261	$ 0	$ 62,184	$ 0

Segment Information - Summary_2

Segment Information - Summary of Company's Adjusted EBITDA (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted EBITDA	$ 38,184	$ 12,210	$ 70,202	$ 21,413
Corporate
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted EBITDA	(7,810)	(2,136)	(14,414)	(3,776)
Radiology | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted EBITDA	35,692	14,346	64,281	25,189
Oncology | Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Adjusted EBITDA	$ 10,302	$ 0	$ 20,335	$ 0

Segment Information - Summary_3

Segment Information - Summary of Net Income (Loss) to Total Adjusted EBITDA (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting [Abstract]
Net loss	$ (26,079)	$ (6,854)	$ (52,511)	$ (9,362)
Interest expense	29,290	8,920	57,971	17,288
Income tax expense (benefit)	(3,483)	6	(2,920)	71
Depreciation and amortization	25,200	4,584	49,931	9,073
EBITDA	24,928	6,656	52,471	17,070
Adjustments:
Restructuring charges	7,244	0	7,324	0
Severance and related costs	5,559	0	7,797	0
Settlements, recoveries and related costs	814	(318)	677	(341)
Stock-based compensation	758	785	1,819	1,212
Loss on disposal of property and equipment, net	170	255	372	346
Acquisition-related costs	86	4,350	468	5,628
Fair value adjustment on derivative in subordinated notes	(1,009)	0	(839)	0
Gain on conversion of debt to equity investment	0	0	0	(3,360)
Deferred rent expense	247	459	579	904
Other, net	(613)	23	(466)	(46)
Adjusted EBITDA	$ 38,184	$ 12,210	$ 70,202	$ 21,413

Segment Information - Schedule

Segment Information - Schedule Of Segment Reporting Information By Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Identifiable assets	$ 1,861,493		$ 1,861,493		$ 1,918,826
Capital expenditures	5,588	$ 1,411	15,466	$ 2,584
Corporate
Segment Reporting Information [Line Items]
Identifiable assets	19,771		19,771		26,505
Capital expenditures	82	0	172	0
Radiology | Operating Segments
Segment Reporting Information [Line Items]
Identifiable assets	1,417,348		1,417,348		1,451,905
Capital expenditures	4,648	1,411	13,460	2,584
Oncology | Operating Segments
Segment Reporting Information [Line Items]
Identifiable assets	424,374		424,374		$ 440,416
Capital expenditures	$ 858	$ 0	$ 1,834	$ 0